Symbol="INKT"
AssetType="Common Stock"
Name="Mink Therapeutics Inc"
Description="MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York."
CIK="1840229"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="65746000"
EBITDA="-29288728"
PERatio="None"
PEGRatio="None"
BookValue="-0.13"
DividendPerShare="0"
DividendYield="0"
EPS="-0.69"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.698"
ReturnOnEquityTTM="-4.037"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.69"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="7"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="11.5"
EVToRevenue="-"
EVToEBITDA="-3.702"
Beta="None"
num_52WeekHigh="4.32"
num_52WeekLow="0.851"
num_50DayMovingAverage="1.979"
num_200DayMovingAverage="2.164"
SharesOutstanding="34422100"
DividendDate="None"
ExDividendDate="None"
symbol="INKT"
open="1.90"
high="2.05"
low="1.90"
price="1.90"
volume="135235.00"
latest_trading_day="2023-07-12"
previous_close="1.91"
change="-0.01"
change_percent="-0.5236%"
aroon_positive_momentum_days="34"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="34"
Volume_recent_avg="124899"
Change_recent_avg="-0.02"
Delta_recent_avg="0.21"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-1.73"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="34"
Aroon_momentum_negative="66"
image_negative_thumbnail_id_1="167"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0009.jpeg"
image_negative_thumbnail_id_2="520"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0085.jpeg"
image_neutral_thumbnail_id_1="585"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0014.jpeg"
image_neutral_thumbnail_id_2="562"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0037.jpeg"
image_positive_thumbnail_id_1="965"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0127.jpeg"
image_positive_thumbnail_id_2="960"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0122.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1178"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0012.jpeg"
